Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin’s lymphoma

References

• Molina A, Al-Kadhimi Z, Nicolaou N. Non-Hodgkin's lymphoma. In: Cancer Management: A Multidisciplinary Approach Pazdur R, Coia LR, Hoskins WJ, Wagman LD (Eds). PRR, Inc., Melville, NY, USA 623–666 (2002).
   Google Scholar
• National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology Vol. 2003. National Comprehensive Cancer Network, Rockledge, PA, USA (2002) (available at www.nccn.org).
   Google Scholar
• Horning S. Follicular lymphoma: have we made any progress? Ann. Oncol 11,23–27 (2000).
   Google Scholar
• Groves F, Linet M, Devesa L, Susan S. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histological subtype in the United States from 1978 and through 1995. j Natl Cancer Inst. 92, 1240–1251 (2000).
   PubMed Web of Science ®Google Scholar
• Fisher R, Gaynor E, Dahlberg S et al.
   Google Scholar
• ••Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl. Med. 328,1002-1006 (1993).
   Google Scholar
• Coiffier B, Lepage E, Briere J et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl. I Ned. 346, 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A et al
   Google Scholar
• •• Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl. Med. 333,1540-1545 (1995).
   Google Scholar
• Fisher R. Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity.' Clin. Oncol 20,4411–4412 (2002).
   Google Scholar
• The International Non-Hodgkin's
   Google Scholar
• •• Lymphoma Prognostic Factors Project. A predictive model for aggressive non Hodgkin's lymphoma. N EngL I Med 329,987-994 (1993).
   Google Scholar
• Colombat P, Foussard C, Bertrand P et al.
   Google Scholar
• •Value of autologous stem cell transplantation in first line therapy of follicular lymphoma with high tumor burden: first results of the randomized GOELAMS 064 trial. Blood 98,861a (2001) (Abstract 3573).
   Google Scholar
• Hiddemann W, Unterhalt M, Wandt H
   Google Scholar
• •et al Myeloablative radiochemotherapy followed by blood stem cell transplantation significantly prolongs the disease—free interval in patients with low grade lymphomas as compared to standard maintenance with interferon a: results of a prospective randomized comparison by the German Low Grade Lymphoma Study Group (GLSG). Blood 96,610a (1999) (Abstract 2715).
   Google Scholar
• Colombat P, Cornillet P, Deconinck E et al Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS Phase II study. Bone MarIVW Transplant. 26, 971–977 (2000).
   PubMed Web of Science ®Google Scholar
• Freedman A, Gribben J, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. B/ooc/88,2780–2786 (1996).
   Google Scholar
• Horning S, Negrin R, Hoppe R et al High- dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a Phase II clinical trial. B/ooc/97,404–409 (2001).
   Google Scholar
• Ladetto M, Corradini P, Vallet S et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italian° Trapianto Midollo Osseo. B/ooc/100,1559–1565 (2002).
   Google Scholar
• VOSO M, Martin S, Hochaus S et al. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Matrow Tansplant. 25,957–964 (2000).
   Google Scholar
• Bouabdallah R, Coso D, Costello R et al. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center. Bone Marrow 71ansplant. 25, 35–40 (2000).
   Google Scholar
• Gianni A, Bregni M, Siena S et al High
   Google Scholar
• •dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl. I Med. 336, 1290–1297 (1997).
   Google Scholar
• Gisselbrecht C, Lepage E, Molina T et al.
   Google Scholar
• •Shortened first-line high-dose chemotherapy for patients with poor prognosis aggressive lymphoma. I Clin. Once'. 20,2472-2479 (2002).
   Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al
   Google Scholar
• •Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. I Clin. OncoL 12, 2543–2551 (1994).
   Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al
   Google Scholar
• •Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH872. Groupe d'Etude des Lymphomes de l'Adulte. I Clin. OncoL 15,1131–1137 (1997).
   Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al
   Google Scholar
• •Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87–2 protocol. A Groupe d'Etude des Lymphomes de l'Adulte Study. I Clin. Oncol 18, 3025–3030 (2000).
   Google Scholar
• Kaiser U, Uebelacker I, Abel U et al.
   Google Scholar
• •Randomized study to evaluate the use of high-dose therapy as part of primary treatment for 'aggressive' lymphoma. Clin. Oncol 20,4413-4419 (2002).
   Google Scholar
• Kewalramani T, Zelenetz A, Hedrick A et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. B/ooc/96,2399–2404 (2000).
   Google Scholar
• Kluin-Nelemans H, Zagonel V,
   Google Scholar
• •Anastasopoulou A et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non Hodgkin's lymphoma: randomized Phase III EORTC study. Natl Cancer Inst. 93,22-30 (2001).
   Google Scholar
• Martelli M, Vignetti M, Zinzani P et al.
   Google Scholar
• •High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-hodgkin's lymphoma with partial response to front line chemotherapy: a prospective randomized Italian multicenter study.
   Google Scholar
• •Clin. Oncol 14,534-542 (1996).
   Google Scholar
• Milpied N, Deconinck E, Colombat P
   Google Scholar
• •et al Frontline high-dose chemotherapy (HDC) with autologous stem cell transplantation vs. standard CHOP regimen for patients (PTS) 60 years old with non-ipi high-risk intermediate or high-grade lymphomas (NHL). Final results of a randomized trial by the GOELAMS. Blood 100 (2002) (Abstract 675).
   Google Scholar
• Moreau P, Milpied N, Voillat L et al Peripheral blood stem cell transplantation as front-line therapy in patients aged 61-65 years: a pilot study. Bone MarMW Warliplant. 21,1193–1196 (1998).
   PubMed Web of Science ®Google Scholar
• Nademanee A, Molina A, O'Donnell M et al Results of high-dose therapy and autologous bone marrow/stem cell transplantation in poor-risk intermediate- and high-grade lymphoma: International Index High and High-Intermediate Risk Group. Blood 90, 3844–3852 (1997).
   PubMed Web of Science ®Google Scholar
• Santini G, Salvagno L, Leoni P et al.
   Google Scholar
• •VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Co-operative Study Group.
   Google Scholar
• •Clin. Oncol 16(8), 2796–2802 (1998).
   Google Scholar
• Stiff P, Dahlberg S, Forman S et al Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens — a Southwest Oncology Group trial. J. Clin. Oncol 16, 48–55 (1998).
   PubMed Web of Science ®Google Scholar
• Stoppa AM, Bouabdallah R, Chabannon C et al Intensive sequential chemotherapy with repeated blood stem cell support for untreated poor-prognosis non-Hodgkin's lymphoma.j Clin. Oncol 15,1722–1729 (1997).
   PubMed Web of Science ®Google Scholar
• Verdonck L, Putten WV, Hagenbeek A
   Google Scholar
• •et al Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non Hodgkin's lymphoma. N Engl. I Med. 332,1045-1051 (1995).
   Google Scholar
• Vita.° U, Cortellazzo S, Liberati A et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J. Gun. Oncol 15,491-498 (1997).
   Google Scholar
• Vose J, Ahang M, Rowlings P et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J. Gun. Oncol 19, 406–413 (2001).
   Google Scholar
• Martelli M, Gherlinzoni F, Renzo AD
   Google Scholar
• •et al Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J. Clin. Oncol 21, 1255–1262 (2003).
   Google Scholar
• Linch D, Yung L, Smith P et al.
   Google Scholar
• •A randomised trial of CHOP x 6–8 vs. CHOP x 3 + BEAM + ASCT in 457 patients with poor prognosis histologically aggressive non-Hodgkin's lymphoma. Ann. Oncol 13,28 (2002) (Abstract 85).
   Google Scholar
• Vika° U, Liberati A, Deliliers G et al.
   Google Scholar
• •High dose chemotherapy (HDS) with autologous stem cell transplantation (ASCT) vs. intensified chemotherapy megaCEOP in high risk diffuse large cell lymphoma (DLCL): an update of a multicenter randomized trial by Italian Lymphoma Intergroup (ILI). Ann. Oncol 13,29 (2002) (Abstract 86).
   Google Scholar
• Sweetenham J. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials? Bone Marrow Transplant. 28,813–820 (2001).
   Google Scholar
• Sweetenham J, Santini G, Qian W et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patient with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J. Clin. Oncol 19, 2927–2936 (2001).
   PubMed Web of Science ®Google Scholar
• Fanin R, Silvestri F, Geromin A et al Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index. Bone Marrow 71ansplant. 21,263-271 (1998).
   Google Scholar
• Pettengell R, Radford J, Morgenstern G et al Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J. Clin. Oncol 14, 586–592 (1996).
   PubMed Web of Science ®Google Scholar
• Kwak L, Halpern J, Olshen RA, S Horning. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J. Clin. Oncol 8, 963–977 (1990).
   PubMed Web of Science ®Google Scholar
• Leleu X, Mounier N, Andre M et al Incidence of secondary leukemias after treatment of high grade NHL with reinforced CHOP (ACVBP) regimen. A co-operative GELA/GFM Study. Blood100 (2002) (Abstract 1284).
   Google Scholar
• Rosenwald A, Wright G, Chan W et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Eng/. I Med. 346,1937–1947 (2002).
   PubMed Web of Science ®Google Scholar
• Winter J, Inwards D, Erwin W et al Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results. Blood100 (2002) (Abstract 1597).
   Google Scholar
• Gopal AK, Rajendran J, Petersdorf S et al High—dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood99, 3158–3162 (2002).
   PubMed Web of Science ®Google Scholar
• Verdonck L, Dekker A, Lokhorst H et al.
   Google Scholar
• •Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. B/ooc/90,4201-4205 (1997).
   Google Scholar
• Khouri I, Keating M, Korbling M et al. Transplant-Lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol 16,2817–2824 (1998).
   PubMed Web of Science ®Google Scholar